The AMR Centre has secured a funding package to support the expansion of its pipeline of new drugs designed to treat drug-resistant infections.

The AMR Centre Team Outside Alderley Park

The AMR Centre Team Outside Alderley Park

The organisation is focused on accelerating the development of new antibiotics and diagnostics. It works with international SMEs and pharmaceutical companies to fast track their potentially vital new products into clinical trials.

It currently has three projects with partners in the UK, Sweden and US.

The £2.3m investment has been led by LifeArc. Other backers include Bruntwood SciTech, MGL, and the Greater Manchester and Cheshire Life Sciences Fund. It comes at a "crucial time in the fight against antimicrobial resistance" following the announcement in January of the UK government's plans to cut inappropriate use of antibiotics and reduce drug resistant infections.

Dr Peter Jackson, executive director of the AMR Centre, said: "We hope that this initial investment by LifeArc, combined with the continued support of our existing investors, will be the start of a fruitful collaboration on our shared mission to deliver new therapies for serious drug resistant infections.

"There is currently a real momentum in the field of AMR research and investments like this are crucial in helping us build the collaborative networks we need to get life-saving drugs to market."

LifeArc chief executive Dr Melanie Lee added: "As a medical charity we are dedicated to accelerating the translation of innovation into new therapies and diagnostics. The AMR Centre's aims align to our therapy area focus on fighting infection, including antimicrobial resistance.

"This is the start of a great collaboration, one which will help enhance this important research."

NewsPatrick Molyneux